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MEETING ABSTRACT Open Access
Integrase inhibitors effective against human T-cell
leukemia virus type 1
Muhammad E Seegulam, Lee Ratner*
From 15th International Conference on Human Retroviruses: HTLV and Related Viruses
Leuven and Gembloux, Belgium. 5-8 June 2011
Drugs targeting the viral enzyme integrase have been in
use for several years as part of the treatment regimen
for patients with Human Immunodeficiency Virus Type
1 (HIV-1) and similar classes of compounds have been
shown to inhibit Human T-Cell Leukemia Virus Type 1
(HTLV-1) integration in vitro. The current study shows
that the clinically approved HIV-1 integrase inhibitor,
Raltegravir, as well as the more recent diketo acid deri-
vative, MK-2048, are active inhibitors of HTLV-1 infec-
tion in vitro. These agents were effective in inhibiting
cell-free and cell-to-cell transmission of HTLV-1 in lym-
phoid and non-lymphoid cells. The drugs also inhibited
HTLV-1 immortalization of human peripheral blood
mononuclear cells. A novel adaptation of the Alu assay
for viral integration was used to show that the drugs
inhibit viral integration without affecting reverse tran-
scription. These data support the administration of Ral-
tegravir and other integrase inhibitors as treatments for
patients with HTLV-1 associated diseases.
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